Amgen, Horizon Blast FTC's 'Speculation On Speculation'

By Bryan Koenig · June 12, 2023, 8:19 PM EDT

Amgen and Horizon Therapeutics insisted that the Federal Trade Commission's challenge to their merger is undone by real-world market dynamics that make it impractical to bundle products that, as the agency...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Federal Trade Commission V. Amgen Inc., et al.

Case Number

1:23-cv-03053

Court

Illinois Northern

Nature of Suit

410(Anti-Trust)

Date Filed

May 16, 2023